Peptides for T cell stimulation
NOW AVAILABLE: SARS-CoV-2 peptides for T cell stimulation
The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a virus that currently needs detailed research to understand underlying immune responses and to provide possible treatment options. In addition, the development of an efficient vaccine is essential to prevent future outbreaks. Studying CD8+ cytotoxic T cell activation and proliferation in response to different virus-derived peptides can help to identify the parts of a virus that elicit a strong immune response. This information is required for efficient vaccine design and contributes to the understanding of the infection biology. We provide different SARS-CoV-2-derived peptides for T cell stimulation to support the ongoing research regarding the new coronavirus.
Products - Collection of peptides
Please use filters "Category" and "Subcategory" to quickly select your product from the list below:
| Product | Contents | Cat.no | Price | Order | |||
|---|---|---|---|---|---|---|---|
| CMV pp65 peptide NLVPMVATV (HLA-A*0201) for stimulation of T-cells | 1 mg | 6-7001-901 | USD 82.00 | ||||
|
CMV pp65 peptide NLVPMVATV (HLA-A0201) for stimulation of T-cells. Single peptide (NLVPMVATV) for stimulation of human CMV-specific CD8+ T-cells. The peptide is synthesised as it is presented by the MHC class I HLA-A*0201 allele. Lyophilized powder. Purity > 85 %, endotoxin free. |
|||||||
| EBV BMLF-1 peptide GLCTLVAML (HLA-A*0201) for stimulation of T-cells | 1 mg | 6-7002-901 | USD 82.00 | ||||
|
EBV peptide GLCTLVAML (HLA-A*0201) for stimulation of T-cells. Single peptide (GLCTLVAML) for stimulation of human EBV BMLF-1(280-288) CD8+ T-cells. The peptide is synthesised as it is presented by the MHC class I HLA-A*0201 allele. Lyophilized powder. Purity > 80 %, endotoxin free. |
|||||||
| Influenza M peptide GILGFVFTL (HLA-A*0201) for stimulation of T-cells | 1 mg | 6-7003-901 | USD 82.00 | ||||
|
Influenza M peptide GILGFVFTL (HLA-A*0201) for stimulation of T-cells. Single peptide (GILGFVFTL) for stimulation of human Influenza M1-specific CD8+ T-cells. The peptide is synthesised as it is presented by the MHC class I HLA-A*0201 allele. Lyophilized powder. Purity > 80 %, endotoxin free. |
|||||||
| HIV gag peptide SLYNTVATL (HLA-A*0201) for stimulation of T-cells | 1 mg | 6-7004-901 | |||||
|
HIV gag peptide SLYNTVATL (HLA-A*0201) for stimulation of T-cells. Single peptide (SLYNTVATL) for stimulation of human HIV gag-specific CD8+ T-cells. The peptide is synthesised as it is presented by the MHC class I HLA-A*0201 allele. Lyophilized powder. Purity > 80 %, endotoxin free. |
|||||||
| HIV pol peptide ILKEPVHGV (HLA-A*0201) for stimulation of T-cells | 1 mg | 6-7005-901 | USD 82.00 | ||||
|
HIV pol peptide ILKEPVHGV (HLA-A*0201) for stimulation of T-cells. Single peptide ( ILKEPVHGV) for stimulation of human HIV pol-specific CD8+ T-cells. The peptide is synthesised as it is presented by the MHC class I HLA-A*0201 allele. Lyophilized powder. Purity > 80 %, endotoxin free. |
|||||||
| HBV core peptide FLPSDFFPSV (HLA-A*0201) for stimulation of T-cells | 1 mg | 6-7006-901 | |||||
|
HBV core peptide FLPSDFFPSV (HLA-A*0201) for stimulation of T-cells. Single peptide (FLPSDFFPSV) for stimulation of human HBV core-specific CD8+ T-cells. The peptide is synthesised as it is presented by the MHC class I HLA-A*0201 allele. Lyophilized powder. Purity > 80 %, endotoxin free. |
|||||||
| MART-1 peptide ELAGIGILTV (HLA-A*0201) for stimulation of T-cells | 1 mg | 6-7007-901 | USD 82.00 | ||||
|
MART 1 peptide ELAGIGILTV (HLA-A*0201) for stimulation of T-cells. Single peptide (ELAGIGILTV) for stimulation of human MART 1-specific CD8+ T-cells. The peptide is synthesised as it is presented by the MHC class I HLA-A*0201 allele. Lyophilized powder. Purity > 80 %, endotoxin free. |
|||||||
| HER-2/neu peptide KIFGSLAFL (HLA-A*0201) for stimulation of T-cells | 1 mg | 6-7008-901 | |||||
|
Her-2/neu peptide KIFGSLAFL (HLA-A*0201) for stimulation of T-cells. Single peptide (KIFGSLAFL) for stimulation of human Her-2/neu-specific CD8+ T-cells. The peptide is synthesised as it is presented by the MHC class I HLA-A*0201 allele. Lyophilized powder. Purity > 80 %, endotoxin free. |
|||||||
| HER-2/neu peptide RLLQETELV (HLA-A*0201) for stimulation of T-cells | 1 mg | 6-7009-901 | |||||
|
Her-2/neu peptide RLLQETELV (HLA-A*0201) for stimulation of T-cells. Single peptide (RLLQETELV) for stimulation of human Her-2/neu-specific CD8+ T-cells. The peptide is synthesised as it is presented by the MHC class I HLA-A*0201 allele. Lyophilized powder. Purity > 80 %, endotoxin free. |
|||||||
| gp100 peptide I MDQVPFSV (HLA-A*0201) for stimulation of T-cells | 1 mg | 6-7010-901 | |||||
|
Gp 100 peptide IMDQVPFSV (HLA-A*0201) for stimulation of T-cells. Single peptide (IMDQVPFSV) for stimulation of human Gp 100-specific CD8+ T-cells. The peptide is synthesised as it is presented by the MHC class I HLA-A*0201 allele. Lyophilized powder. Purity > 80 %, endotoxin free. |
|||||||
| gp100 peptide ITDQVPFSV (HLA-A*0201) for stimulation of T-cells | 1 mg | 6-7011-901 | |||||
|
Gp 100 peptide ITDQVPFSV (HLA-A*0201) for stimulation of T-cells. Single peptide (ITDQVPFSV) for stimulation of human Gp 100-specific CD8+ T-cells. The peptide is synthesised as it is presented by the MHC class I HLA-A*0201 allele. Lyophilized powder. Purity > 80 %, endotoxin free. |
|||||||
| Tyrosinase peptide YMDGTMSQV (HLA-A*0201) for stimulation of T-cells | 1 mg | 6-7012-901 | |||||
|
Tyrosinase peptide YMDGTMSQV (HLA-A*0201) for stimulation of T-cells. Single peptide (YMDGTMSQV) for stimulation of human Gp 100-specific CD8+ T-cells. The peptide is synthesised as it is presented by the MHC class I HLA-A*0201 allele. Lyophilized powder. Purity > 80 %, endotoxin free. |
|||||||
